What Happened this Week? Human Embryos Back on the Bench, Stem Cells in your Heart and New Antibiotics

September 27, 2015 - 1 minute

Monday: Nabriva Therapeutics launched its $100M IPO on the NASDAQ to develop new antibiotics


 

Tuesday: the Francis Crick Institute announced its application to conduct new research on human embryos


 

Wednesday: Israeli NovoCure announced an IPO on NASDAQ with a target of €170M


 

Content continues below

Related Content

Thursday: Belgian TiGenix NV released the phase I results of their cardiac stem-cell therapy


 

Friday: in a successful phase III trial, the Amgen biosimilar showed full-efficacy equivalent to Roche‘s Avastin

You might also be interested in the following: